10-Q · May 13, 2026
Journey Medical Corporation reported Q1 2026 revenues of $15.96 million, reflecting a 21% increase year-over-year. The net loss narrowed significantly to $2.23 million from $4.07 million in the prior year. Management…
Earnings analysis · 10-Q
DERM earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
Q2 revenue was $17.839 million and diluted EPS was $(0.01), with revenue missing consensus by approximately 3.2% but EPS beating the $0.02 estimate by $0.01. The supplied 10-Q extract does not include the financial…
Read full summary
Q2 revenue was $17.839 million and diluted EPS was $(0.01), with revenue missing consensus by approximately 3.2% but EPS beating the $0.02 estimate by $0.01. The supplied 10-Q extract does not include the financial statements or MD&A, so gross margin, operating margin, segment performance, cash flow, free cash flow, balance-sheet changes, and quantitative outlook cannot be reliably assessed. Risk factors were incorporated by reference to the 2025 Form 10-K, with no specific new risk-factor changes identified.
Reported figures
- Earnings per share
- $-0.01
What stood out
-
Revenue Missed Consensus
Q2 revenue was $17.839 million, below the $18.4372 million consensus estimate by approximately 3.2%.
-
EPS Beat Consensus
Diluted EPS was $(0.01), better than the $(0.02) consensus estimate by $0.01 per share.
-
Disclosure Controls Effective
The company states that its disclosure controls and procedures were effective as of June 30, 2026.
-
No Material Control Changes
No material change in internal control over financial reporting occurred during the quarter, according to management.
What to watch
-
Prior-Year Risks Remain Applicable
The company states that the risk factors disclosed in its 2025 Form 10-K continue to apply and may materially affect its business, financial condition, or results of operations; no newly quantified risk-factor change was provided in this 10-Q.
-
Potential Litigation Exposure
No material legal proceedings are pending other than routine actions, administrative proceedings, and other actions; however, the company notes that insured and uninsured litigation may arise in the ordinary course.
-
Limited Liquidity Disclosure
The filing provides no quantitative balance-sheet or cash-flow detail in the supplied extract, limiting assessment of liquidity, debt, inventory, receivables, and operating cash-flow risk.
Management's outlook
The 10-Q does not provide explicit numeric revenue or EPS guidance; no forward quantitative outlook was identified.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.